Spots Global Cancer Trial Database for parpi
Every month we try and update this database with for parpi cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors | NCT03911453 | Breast Cancer | Rucaparib | 21 Years - | University of Arizona | |
| Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer | NCT05446545 | Ovarian Cancer | ND-EOC or plati... | 18 Years - 70 Years | Fudan University | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | NCT03901469 | Triple Negative... | ZEN003694 Talazoparib | 18 Years - | Zenith Epigenetics | |
| Effect of PARP Inhibitors on Glomerular Filtration Rate | NCT04367467 | Solid Tumor Ovarian Cancer Breast Cancer | Kidney Function... | 18 Years - | University of Pennsylvania | |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma | NCT03397394 | Bladder Cancer Urothelial Carc... Metastatic Urot... Renal Pelvis Ca... Ureter Carcinom... Urinary Bladder... Urethra Carcino... Muscle Invasive... | Rucaparib | 18 Years - | pharmaand GmbH | |
| CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib | NCT04676334 | Metastatic Cast... Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Peritoneal Canc... Other Solid Tum... | Rucaparib | 18 Years - | pharmaand GmbH | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | NCT02854436 | Prostatic Neopl... | Niraparib | 18 Years - | Janssen Research & Development, LLC | |
| Chemo-free BRCA-targeted Neoadjuvant Strategy | NCT05209529 | TNBC - Triple-N... BRCA1 Mutation BRCA2 Mutation | olaparib Durvalumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer | NCT04518501 | Efficacy and Sa... | Arsenic trioxid... | 18 Years - 70 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer | NCT04518501 | Efficacy and Sa... | Arsenic trioxid... | 18 Years - 70 Years | Women's Hospital School Of Medicine Zhejiang University | |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency | NCT02975934 | Metastatic Cast... | Rucaparib Abiraterone ace... | 18 Years - | pharmaand GmbH | |
| A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes | NCT04171700 | Solid Tumor | Rucaparib | 18 Years - | pharmaand GmbH | |
| Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer | NCT04518501 | Efficacy and Sa... | Arsenic trioxid... | 18 Years - 70 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Effect of PARP Inhibitors on Glomerular Filtration Rate | NCT04367467 | Solid Tumor Ovarian Cancer Breast Cancer | Kidney Function... | 18 Years - | University of Pennsylvania | |
| Chemo-free BRCA-targeted Neoadjuvant Strategy | NCT05209529 | TNBC - Triple-N... BRCA1 Mutation BRCA2 Mutation | olaparib Durvalumab | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Effect of PARP Inhibitors on Glomerular Filtration Rate | NCT04367467 | Solid Tumor Ovarian Cancer Breast Cancer | Kidney Function... | 18 Years - | University of Pennsylvania | |
| An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies | NCT02854436 | Prostatic Neopl... | Niraparib | 18 Years - | Janssen Research & Development, LLC | |
| Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | NCT04515602 | Epithelial Ovar... Fallopian Tube ... Primary Periton... | Primary debulki... Neoadjuvant che... PARPi | 18 Years - | Shanghai Gynecologic Oncology Group | |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | NCT03824704 | Epithelial Ovar... Fallopian Tube ... Primary Periton... High Grade Sero... Endometrioid Ad... | Rucaparib Nivolumab | 18 Years - | pharmaand GmbH | |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | NCT03901469 | Triple Negative... | ZEN003694 Talazoparib | 18 Years - | Zenith Epigenetics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
